Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) · 2025
Optimizing the anticancer action and toxicity evaluation of cobalt ferrite nanoparticles by different polyethylene glycol concentrations.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Akhtar Kanwal, Abbas Muhammad Khawar, Muzammil Nida, Shad Naveed Akhtar, Iqbal Qaisar, Abbas Wasim, Muhammad Faqir, Akhtar Bushra, Javed Yasir, Khadim Habiba, Munawar Anam
Аннотация
BACKGROUND: Polyethylene glycol (PEG) as a coating agent enhances the circulation time of nanoparticles (NPs) and shields the inorganic core from the immediate cell-mediated immune response. Cobalt ferrite (CoFe2O4) has shown promising potential due to its magnetic properties and is also widely used to stimulate targeted responsive drug deposition mechanisms to treat localized cancerous cells.
METHODOLOGY: In this study, the anticancer potential of CoFe2O4 NPs was optimized by coating the NPs with different PEG concentrations. The synthesized CoFe2O4 NPs have a crystallite size of 15.7 nm, determined by X-ray diffraction (XRD) analysis. Coating concentrations were verified by Fourier Transform Infrared (FTIR) spectroscopy and Dynamic Light Scattering (DLS) analysis. The surface charge of the CoFe2O4 NPs increased from -16.04-43.88 mV for different PEG concentrations. The CoFe2O4 NPs functionalized with varying PEG concentrations, i.e., 0.1, 0.125, and 0.25 g, were used to obtain the optimum anticancer action against the human embryonic kidney cancerous (HEK293T) cell line.
RESULTS: The IC50 value for bare CoFe2O4 NPs was 76.943 μg/mL, however, the optimum response was received when CoFe2O4 NPs were coated with PEG0.25 with an IC50 value of 35.762 μg/mL. This indicates a significant improvement in the anticancer property of CoFe2O4 NPs with polymer coating. To ensure the safe application of CoFe₂O₄ NPs, in vivo toxicity studies were conducted in albino rats. Results indicated a dose-dependent hepatotoxicity and nephrotoxicity, with elevated levels of liver enzymes (AST > 200 U/L and ALT > 60 U/L) and increased blood urea nitrogen (BUN ≥ 70 mg/dL), signaling potential organ damage at higher doses. These findings emphasize the need for careful consideration of both the therapeutic efficacy and safety profile when using CoFe₂O₄ NPs for cancer treatment.
METHODOLOGY: In this study, the anticancer potential of CoFe2O4 NPs was optimized by coating the NPs with different PEG concentrations. The synthesized CoFe2O4 NPs have a crystallite size of 15.7 nm, determined by X-ray diffraction (XRD) analysis. Coating concentrations were verified by Fourier Transform Infrared (FTIR) spectroscopy and Dynamic Light Scattering (DLS) analysis. The surface charge of the CoFe2O4 NPs increased from -16.04-43.88 mV for different PEG concentrations. The CoFe2O4 NPs functionalized with varying PEG concentrations, i.e., 0.1, 0.125, and 0.25 g, were used to obtain the optimum anticancer action against the human embryonic kidney cancerous (HEK293T) cell line.
RESULTS: The IC50 value for bare CoFe2O4 NPs was 76.943 μg/mL, however, the optimum response was received when CoFe2O4 NPs were coated with PEG0.25 with an IC50 value of 35.762 μg/mL. This indicates a significant improvement in the anticancer property of CoFe2O4 NPs with polymer coating. To ensure the safe application of CoFe₂O₄ NPs, in vivo toxicity studies were conducted in albino rats. Results indicated a dose-dependent hepatotoxicity and nephrotoxicity, with elevated levels of liver enzymes (AST > 200 U/L and ALT > 60 U/L) and increased blood urea nitrogen (BUN ≥ 70 mg/dL), signaling potential organ damage at higher doses. These findings emphasize the need for careful consideration of both the therapeutic efficacy and safety profile when using CoFe₂O₄ NPs for cancer treatment.